Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24030098 | 0.79 | DRD2 (0.47) | DRD2MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4024516 | 0.76 | DRD2 (0.56) | DRD2MEN1KMT2AACHEBACE1 | |
| SCHEMBL5406828 | 0.76 | HTR3A (0.59) | MEN1KMT2APOLBRAB9A | |
| SCHEMBL5409909 | 0.75 | MCHR1 (0.56) | MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL485945 | 0.74 | DRD2 (0.55) | DRD2MEN1KMT2AALDH1A1ACHE | |
| SCHEMBL7220892 | 0.74 | DRD2 (0.55) | DRD2MEN1KMT2AALDH1A1ACHE | |
| Hydrochloric Acid SCHEMBL11640831 | 0.74 | LMNA (0.57) | DRD2LMNAMEN1KMT2APOLB | |
| SCHEMBL5403785 | 0.74 | DRD2 (0.43) | DRD2MEN1KMT2APOLBALDH1A1 | |
| Biphenyl SCHEMBL28784863 | 0.73 | DRD2 (0.62) | DRD2SIGMAR1ACHEBACE1 | |
| Hydrochloric Acid SCHEMBL11641349 | 0.73 | LMNA (0.54) | LMNAMEN1KMT2APOLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | DRD2 3203/4885LMNA 2974/4885MEN1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.